tradingkey.logo

Dexcom Inc

DXCM
View Detailed Chart

75.865USD

-0.355-0.47%
Market hours ETQuotes delayed by 15 min
29.75BMarket Cap
52.06P/E TTM

Dexcom Inc

75.865

-0.355-0.47%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.47%

5 Days

-5.77%

1 Month

-5.12%

6 Months

+7.32%

Year to Date

-2.45%

1 Year

+9.14%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
26 / 207
Overall Ranking
134 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 29 analysts
Buy
Current Rating
103.329
Target Price
+35.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 68.87.
Undervalued
The company’s latest PE is 52.28, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 390.97M shares, decreasing 6.58% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 48.15M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Ticker SymbolDXCM
CompanyDexcom Inc
CEOMr. Jacob Steven (Jake) Leach
Websitehttps://www.dexcom.com/
KeyAI